Acridines (including Hydrogenated) Patents (Class 514/297)
-
Patent number: 5710169Abstract: Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA are useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: October 24, 1995Date of Patent: January 20, 1998Assignee: Zeneca LimitedInventor: Keith Russell
-
Patent number: 5698224Abstract: A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy.Type: GrantFiled: June 27, 1994Date of Patent: December 16, 1997Assignee: Alza CorporationInventors: George V. Guittard, Jerry D. Childers, Patrick S. -L. Wong, Fernando E. Gumucio, David J. Kidney
-
Patent number: 5696131Abstract: A new treatment schedule for administration of N-?2-(dimethylamino)ethyl!acridine-4-carboxamide and other related carboxamide anticancer drugs in which the drug is administered in a divided-dose schedule comprising two or more administrations at frequent intervals, for example every hour. Schedules to produce cyclic peaks/troughs in plasma levels are mentioned. The compounds can be used for circumventing multidrug resistance in cancers and may, for example, be used in combination with other cytotoxic drugs, especially non-topo II inhibitors. Treatment of melanoma and advanced colon cancer is included.Type: GrantFiled: February 13, 1995Date of Patent: December 9, 1997Assignee: Xenova LimitedInventors: Bruce Charles Baguley, Graham John Atwell, William Alexander Denny, Graeme John Finlay, Gordon William Rewcastle
-
Patent number: 5693649Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: October 18, 1995Date of Patent: December 2, 1997Assignee: Novo Nordisk A/SInventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
-
Patent number: 5691132Abstract: Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes. In particular, quinacrine mustard is used to inactivate pathogens in red cell compositions with retention of red cell function.Type: GrantFiled: November 14, 1994Date of Patent: November 25, 1997Assignee: Cerus CorporationInventors: Susan Wollowitz, David Cook, Aileen Nerio
-
Patent number: 5688788Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: May 18, 1995Date of Patent: November 18, 1997Assignee: Novo Nordisk A/SInventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
-
Patent number: 5670513Abstract: The present invention provides a medicinal feed for fish, which comprises a triphenylmethane derivative or a combination of triphenylmethane derivatives alone or in combination with at least one compound selected from the group consisting of thionine, nitrothiazole, nitrofuran, quinoline and acridine derivatives, compounds splitting off aldehydes, transition metal derivatives, metal colloids, hexamethylenetetramine and/or quaternary ammonium salts as active materials.Type: GrantFiled: July 10, 1995Date of Patent: September 23, 1997Assignee: Tetra Werke Dr. Rer. Nat. U. Baensch GmbHInventors: Hartmut Schmidt, Gunter Ritter
-
Patent number: 5668129Abstract: The present invention relates to novel N-substituted azaheterocyclic carboxylic acids and esters thereof in which a substituted alkyl chain forms part of the N-substituent or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.Type: GrantFiled: March 27, 1996Date of Patent: September 16, 1997Assignee: Novo Nordisk A/SInventors: Knud Erik Andersen, Uffe Bang Olsen, Hans Petersen, Frederik Christian Gr.o slashed.nvald, Ursula Sonnewald, Tine Krogh J.o slashed.rgensen, Henrik Sune Andersen
-
Patent number: 5663179Abstract: Compounds are described of general formula (I) ##STR1## and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which:Z represents either Het, ##STR2## Het represents an optionally substituted bicyclic or tricyclic ring selected from acricine isoquinolin-1-yl, isoquinolin-3-yl,The novel compounds of formula (I) can sensitize multi-drug resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an anti-tumour drug.Type: GrantFiled: December 29, 1994Date of Patent: September 2, 1997Assignee: Laboratoires Glaxo SAInventors: Bernard Andre Dumaitre, Nerina Dodic, Alain Claude-Marie Daugan, Pascal Maurice Charles Pianetti
-
Patent number: 5658886Abstract: The claims cover a bioactive compound N-methyl-N-.alpha.-D-glucopyranosil-ammonium-2-acridone-9-on-10-yl-acetate designated CYCLOFERONE which was obtained by chemical synthesis and is a heterocyclic compound. Specifically CYCLOFERONE is an acridanone derivative of formula ##STR1## CYCLOFERONE exhibits interferonogenic, anti-vital (including anti-HIV), anti-parasitic, anti-promotive, and radioprotective effects.Type: GrantFiled: December 7, 1994Date of Patent: August 19, 1997Assignee: Limited Liability Partnership "POLYSAN"Inventors: Novomir Pavlovich Chizhov, Roald Antonovich Kupchinsky, Ljudmila Evgenievna Alekseeva, Aleksei Leonidovich Kovalenko, Margarita Alekseevna Borisova
-
Patent number: 5641783Abstract: Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocycle. R.sub.3 may be either hydrogen or C.sub.1-3. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.Type: GrantFiled: September 8, 1994Date of Patent: June 24, 1997Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Anil M. Kumar
-
Patent number: 5622964Abstract: Methods of treating asthma are provided which methods comprise administering to a mammal in need of such treatment an effective amount of a compound of Formula I ##STR1## or a pharmaceutically acceptable salt thereof wherein R.sup.2, R.sup.3, R.sup.4, R.sup.10 and R.sup.11 have any of the meanings given in the specification.Type: GrantFiled: August 18, 1995Date of Patent: April 22, 1997Assignee: Zeneca LimitedInventors: Cyrus J. Ohnmacht, Jr., Diane A. Trainor, Janet M. Forst, Mark M. Stein, Robert J. Harris
-
Patent number: 5618831Abstract: A pharmaceutical composition for treatment of cancer in an animal comprising:(A) a therapeutically effective amount of at least one compound selected from the group consisting of compounds represented by the General Formula (I). ##STR1## wherein Z.sub.1 and Z.sub.2, which may be the same or different, each represents an atomic group necessary to form a 5- or 6-membered ring;R.sub.1, R.sub.2 and R.sub.3, which may be the same or different, each represents an alkyl group or an aryl group;L.sub.1 and L.sub.2 each represents a methine group or a substituted methine group;X represents a pharmaceutically acceptable anion;k represents a number necessary for electrical charge balance;n represents 0 or 1; and(B) a pharmaceutically acceptable carrier or diluent.Type: GrantFiled: May 16, 1994Date of Patent: April 8, 1997Assignees: Fuji Photo Film Co., Ltd., Dana Farber Cancer InstituteInventors: Tadao Shishido, Masayuki Kawakami, Akihiko Ikegawa, Toshinao Ukai, Keizo Koya, Lan B. Chen
-
Patent number: 5605905Abstract: Azaanthracene-triones of the formula: ##STR1## (in which: R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are the same or are different and each is a hydrogen atom or a lower alkyl group;R.sup.3 is a hydrogen atom, a lower alkyl group, a phenyl group or an amino-substituted phenyl group; andX is a --CH--, .dbd.N-- or --NH--, whereby the ring containing the group X is a benzene, pyridine or dihydropyridene ring)have antitumoral activity.Type: GrantFiled: March 28, 1995Date of Patent: February 25, 1997Assignee: Universidad Complutense de MadridInventors: Carmen Avendano, Miguel A. Alonso, Modesta Espada, Dolores Garcia-Gravalos, Jose C. Mendendez, Blanca Ocana, Jose M. Perez
-
Patent number: 5604237Abstract: These are provided compounds of formula I ##STR1## wherein A represents an oxygen or a sulphur atom, a bond or a group (CH.sub.2).sub.1 NR.sup.9 (where 1 represents zero or 1 and R.sup.9 represents a hydrogen atom or a methyl group); B represents a C.sub.1-4 alkylene chain optionally substituted by a hydroxyl group, except that the hydroxyl group and moiety A can not be attached to the same carbon atom when A represents an oxygen or sulphur atom or a group (CH.sub.2).sub.1 NR.sup.9, or when A represents a bond B may also represent a C.sub.2-4 alkenylene chain; R.sup.3 represents a hydrogen atom or a C.sub.1-4 alkyl group; m represents 1 or 2; R.sup.7 represents a hydrogen atom or R.sup.3 and R.sup.7 together form a group --(CH.sub.2).sub.n -- where n represents 1 or 2. These compounds can sensitize multidrug-resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an antitumor drug.Type: GrantFiled: June 6, 1995Date of Patent: February 18, 1997Assignee: Laboratoires Glaxo SAInventors: Bernard A. Dumaitre, Nerina Dodic
-
Patent number: 5602142Abstract: Hypoxia selective cytotoxins having the structural formula ##STR1## wherein D, E, F and G, independently, are carbon or nitrogen, with the proviso that three or more of D, E, F and G are carbon; R.sub.1 and R.sub.2, independently, are selected from the group consisting of methyl, halo, hydro, trifluoromethyl, methoxy, cyano, and methylsulfo; R.sub.3 and R.sub.4, independently, are selected from the group consisting of methyl, ethyl, phenyl, naphthyl, tertiary butyl, halo, halomethylene, hydro, trifluoromethyl, cyano and methylsulfo, or R.sub.3 and R.sub.4 taken together are a substituted or unsubstituted five or six-membered nonaromatic ring system; n is an integer 1 through 5; X is carbon or nitrogen; and Z is a physiologically acceptable anion, are disclosed. The compounds are useful as radiosensitizers or chemosensitizers, especially in the treatment of cancer patients.Type: GrantFiled: December 21, 1994Date of Patent: February 11, 1997Assignee: Evanston Hospital CorporationInventors: Maria V. Papadopoulou-Rosenzweig, William D. Bloomer
-
Patent number: 5595875Abstract: A method for the detection of an analyte in a fluid sample using liposomes encapsulating acridinium esters (lumisomes). Hydrophilic polysubstituted aryl acridinium esters are useful as chemiluminescent markers and can be encapsulated within liposome vesicles without significant leakage of the esters from the vesicles. The lumisomes can be coupled to molecules with biological activity, such as antigens, antibodies, and nucleic acids, and used in luminescent assays.Type: GrantFiled: October 19, 1994Date of Patent: January 21, 1997Assignee: Ciba Corning Diagnostics Corp.Inventors: Say-Jong Law, Uri Piran
-
Patent number: 5583148Abstract: This invention relates to new pyridyl, quinoline and acridine bis-acyloxymethyl compounds; to compositions comprising these compounds; and to processes for their utility as fungicides, bactericides and as inhibitors of the growth of cancer in warm-blooded animals.Type: GrantFiled: July 15, 1991Date of Patent: December 10, 1996Assignee: Research Foundation Of State University Of New YorkInventors: Wayne K. Anderson, Dennis C. Dean
-
Patent number: 5567716Abstract: Traumatic acid salts, wherein B is a cation selected from:a) a quaternary ammonium,b) a cation of a linear or branched C.sub.1 -C.sub.20 mono-, di- or trialkanolamine,c) a cation of a biologically active primary, secondary or tertiary amine,d) silver or zinc cation,and relative pharmaceutical compositions administrable by topical or parenteral route For the therapeutic treatment of cutaneous pathologies in which it is important to associate an a bacteriostatic, antibiotic, antifungal or an antiviral activity, to the cicatrizant effect, typical of traumatic acid.Type: GrantFiled: November 19, 1993Date of Patent: October 22, 1996Assignee: Lifegroup S.p.A.Inventors: Francesco Della Valle, Silvana Lorenzi, Gabriele Marcolongo
-
Patent number: 5550110Abstract: Novel antagonists of endothelin are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin, acute and chronic renal failure, hypertension, myocardial infarction, metabolic, endocrinological, neurological disorders especially cerebral vasospasm, stroke, and head injury, congestive heart failure, endotoxic shock, subarachnoid hemorrhage, arrhythmias, asthma, preeclampsia, atherosclerotic disorders including Raynaud's disease, restenosis, angina, cancer, pulmonary hypertension, ischemic disease, gastric mucosal damage, hemorrhagic shock, ischemic bowel disease, and diabetes.Type: GrantFiled: June 30, 1994Date of Patent: August 27, 1996Assignee: Warner-Lambert CompanyInventors: Wayne L. Cody, Annette M. Doherty, John G. Topliss
-
Patent number: 5550134Abstract: The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.Type: GrantFiled: May 10, 1995Date of Patent: August 27, 1996Assignee: Eli Lilly and CompanyInventors: James E. Audia, Blake L. Neubauer
-
Patent number: 5543433Abstract: Compounds of the formula I ##STR1## where X is hydrogen, halogen, alkyl, alkoxy, trifluoromethyl, cyano or nitro,Y is an amino, methylamino or dimethylamino group,Z is a group CHCH.sub.3, CHOCH.sub.3 or NOCH.sub.3,R is hydrogen or alkyl,A is hydrogen, alkyl, haloalkyl or cycloalkyl,B is unsubstituted or substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl or the group ##STR2## where W is hydrogen, alkyl, alkoxy, alkylthio, alkylamino or dialkylamino, unsubstituted or substituted aryl or heteroaryl, unsubstituted or substituted aryloxy, arylthio, arylamino or aryl-N-(C.sub.1 -C.sub.6 -alkyl)amino, heteroaryloxy, heteroarylthio, heteroarylamino or heteroaryl-N-(alkyl)amino orA and B, together with the C atom whose substituents they are, are an isocyclic or heterocyclic ring which can also be quinonoid,and fungicides containing these compounds.Type: GrantFiled: June 3, 1994Date of Patent: August 6, 1996Assignee: BASF AktiengesellschaftInventors: Reinhard Doetzer, Hubert Sauter, Herbert Bayer, Franz Roehl, Gisela Lorenz, Eberhard Ammermann, Horst Wingert
-
Patent number: 5536728Abstract: A novel 4-acylaminopyridine derivative represented by the following formula (I) is disclosed. ##STR1## The 4-acylaminopyridine derivative of the present invention is useful as a medicine for treating disturbances of memory such as senile dementia and Alzheimer's disease, since it has an action of directly activating malfunctioned cholinergic neuron.Type: GrantFiled: December 8, 1994Date of Patent: July 16, 1996Assignee: Mitsubishi Chemical CorporationInventors: Kunihiro Ninomiya, deceased, Ken-ichi Saito, Mamoru Sugano, Akihiro Tobe, Yasuhiro Morinaka, Tomoko Bessho, Haruko Harada
-
Patent number: 5514686Abstract: Macrolide compounds such as the FR-900506 and its related compounds are provided for the prevention or treatment of eye diseases, particularly, allergic conjunctivitis. Composition containing such compounds is also disclosed.Type: GrantFiled: April 1, 1994Date of Patent: May 7, 1996Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Manabu Mochizuki, Yoichi Iwaki
-
Patent number: 5508289Abstract: The present invention provides an anticancer compound having the structure: ##STR1## wherein R is --H, --CH.sub.3, or --C.sub.2 H.sub.5 ; R1 and R2 are independently --H, --OH, --NH.sub.2, --OCH.sub.3, --C(CH.sub.3).sub.3, or a halogen atom; n is 2 to 6; X and X' are independently --N or --NO.sub.2 ; Y and Y' are independently --N, --CH, or --H; and the double-slash represents a double bond or no bond; such that when X or X' is --N, Y or Y' is --CH or --N, and the double-slash is a double bond, and when X or X' is --NO.sub.2, Y or Y' is --H, and the double-slash is no bond. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier.Type: GrantFiled: March 14, 1994Date of Patent: April 16, 1996Assignee: The United States America as represented by the Department of Health and Human ServicesInventors: Christopher J. Michejda, Wieslaw M. Cholody, Lidia Hernandez
-
Patent number: 5489603Abstract: An insecticidal composition containing a guanidine derivative of the formula: ##STR1## wherein R.sup.1 is an optionally substituted homocyclic or heterocyclic group, n is 0 or 1, R.sup.2 is a hydrogen atom or an optionally substituted hydrocarbon group, R.sup.3 is a primary, secondary or tertiary amino group, X is an electron attractive group such as nitro or trifluoroacetyl group, provided that when n is 0, R.sup.1 is an optionally substituted heterocyclic group or a salt thereof.Type: GrantFiled: July 15, 1993Date of Patent: February 6, 1996Assignee: Takeda Chemical Industries, Ltd.Inventors: Hideki Uneme, Koichi Iwanaga, Noriko Higuchi, Isao Minamida, Tetsuo Okauchi
-
Patent number: 5489590Abstract: A therapeutic composition derived from a pre-activated photoactive compound and a conveyor for destroying tumor or other pathogenic biological contaminants infecting animal body tissues. The conveyor can either be a matrix support or an antibody. The activation of the photoactive compound to produce the pre-activated photoactive compound is carried out by the use of an activating agent. The pre-activated photoactive compound retains its therapeutic activity subsequent to activation. A method for preparing such a therapeutic composition is disclosed. Methods for treating animal body tissue, either outside the body or inside the body, infected with tumors or other pathogenic biological contaminants are disclosed.Type: GrantFiled: February 3, 1992Date of Patent: February 6, 1996Assignee: Baylor Research FoundationInventors: Kirpal S. Gulliya, Shazib Pervaiz, J. Lester Matthews, Robert M. Dowben, Jospeh T. Newman, Edward Forest
-
Patent number: 5484792Abstract: Compounds of general formula I, ##STR1## and pharmaceutically acceptable salts thereof, in which R.sup.1 has any of the meanings given in the specification, pharmaceutical compositions comprising them and their use in the treatment of urinary incontinence.Type: GrantFiled: February 8, 1994Date of Patent: January 16, 1996Assignee: Imperial Chemical Industries, plcInventors: Cyrus J. Ohnmacht, Robert J. Harris, Diane A. Trainor
-
Patent number: 5478837Abstract: Compositions and methods for prevention of adhesion formation, whereby an effective amount of quinacrine as active agent is administered for a period of time sufficient to permit tissue repair. The active agent is preferably administered in conjunction with a delivery vehicle (e.g., microcapsules, microspheres, lipid-based systems, viscous instillates and absorbable mechanical barriers) useful for maintaining local concentrations of the compound at an effective level.Type: GrantFiled: June 7, 1994Date of Patent: December 26, 1995Assignee: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. Dizerega
-
Patent number: 5466696Abstract: Described is a method of treating Alzheimer's disease in a patient comprising administering to said patient an effective amount of tacrine in combination with a P450 1A2 oxidase inhibitor. Preferably, the inhibitor is a heterocyclic guanidine.Type: GrantFiled: August 9, 1993Date of Patent: November 14, 1995Assignee: Warner Lambert CompanyInventor: Thomas F. Woolf
-
Patent number: 5457122Abstract: The phenylalkan(en)oic acids of the formula: ##STR1## as defined herein, possess an antagonistic activity on leukotriene B.sub.4.Type: GrantFiled: July 13, 1993Date of Patent: October 10, 1995Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Mitoshi Konno, Takahiko Nakae, Nobuyuki Hamanaka
-
Patent number: 5455253Abstract: Compounds of formula I ##STR1## wherein R.sup.2, R.sup.3, R.sup.4, R.sup.10 and R.sup.11 have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinery incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: April 14, 1994Date of Patent: October 3, 1995Assignee: Zeneca LimitedInventors: Cyrus J. Ohnmacht, Jr., Diane Trainor, Janet M. Forst, Mark M. Stein, Robert J. Harris
-
Patent number: 5447960Abstract: A plant fungicide method comprises applying to the locus of a plant pathogen a fungicidally effective amount of a compound of formula (I) ##STR1## or a salt or a complex thereof, wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, and R.sup.8 are independently H, halo, NO.sub.2, (C.sub.1 -C.sub.4) alkyl, or halo(C.sub.1 -C.sub.4) alkyl;R.sup.3', R.sup.4', R.sup.5', R.sup.3", R.sup.4", and R.sup.5" are independently H, halo, OH, or CH.sub.3, provided that at least one is OH;R.sup.6 ' and R.sup.6 " are independently H or OH.Type: GrantFiled: October 4, 1993Date of Patent: September 5, 1995Assignee: DowElancoInventors: Deirdre M. Sinnott, Hak-Fun Chow, Robert J. Ehr, Steven D. Lubetkin, Stephen E. Bales, Muthiah N. Inbasekaran
-
Patent number: 5434170Abstract: A method for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state.Type: GrantFiled: December 23, 1993Date of Patent: July 18, 1995Assignee: Andrulis Pharmaceuticals Corp.Inventor: Peter J. Andrulis, Jr.
-
Patent number: 5430039Abstract: A method for inhibiting neuronal cell death in a mammal resulting from a disorder of the central or peripheral nervous system including administering to the mammal a neuronal cell death inhibitng amount of a preparation including any of mepacrine, chloroquine, or hydroxychloroquine, the preparation being essentially free of colchicine.Type: GrantFiled: March 8, 1994Date of Patent: July 4, 1995Assignee: Cephalon, Inc.Inventors: Jill M. Roberts-Lewis, Michael E. Lewis
-
Patent number: 5422350Abstract: Described is a method of inhibiting the enzymatic metabolism of nitrogen substituted acridines of Formula 1 comprising co-administering with the acridine an effective oxidase inhibiting amount of a P450 1A2 inhibitor. The oxidase is one whose activity is induced by beta-naphthaflavone, 3-methylcholanthrene, arochlor, 2,3,7,8-tetrachlorodibenzo-p-dioxin and isosafrole. The oxidase inhibitor may be a naphthyridine, a xanthine, a phenoxy amino alkane, a carbamoyl imidazole, a heterocyclic guanidine, or a quinoline.Type: GrantFiled: September 10, 1992Date of Patent: June 6, 1995Assignee: Warner-Lambert CompanyInventor: Thomas F. Woolf
-
Patent number: 5391553Abstract: There are disclosed compounds having the formula ##STR1## wherein n is 1-4; X is alkyl of 3-18 carbon atoms, cycloalkyl of 3-7 carbon atoms or cycloalkylloweralkyl; R is hydrogen, loweralkyl or loweralkylcarbonyl; R.sub.1 is hydrogen, loweralkyl, loweralkylcarbonyl, aryl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, oxygen-bridged arylloweralkyl or oxygen-bridged diarylloweralkyl; stereo isomers thereof and pharmaceutically acceptable acid addition salts thereof, which are useful for enhancing memory, methods for synthesizing them, and pharmaceutical compositions comprising an effective memory enhancing amount of such a compound.Type: GrantFiled: September 14, 1988Date of Patent: February 21, 1995Assignee: Hoechst-Roussel Pharmaceuticals Inc.Inventors: Gregory M. Shutske, Grover C. Helsley, Kevin J. Kapples
-
Patent number: 5382594Abstract: Novel 9-aminotetrahydroacridines and related compounds, intermediates and processes for the preparation thereof, and a method of relieving memory dysfunction are disclosed.Type: GrantFiled: March 1, 1993Date of Patent: January 17, 1995Assignee: Hoechst-Roussel Pharmaceuticals Inc.Inventors: Gregory M. Shutske, Kevin J. Kapples, John D. Tomer
-
Patent number: 5342752Abstract: A method is provided for inactivating viral and/or bacterial and/or parasitic contamination in cellular blood matter or blood plasma protein fractions, using radiation sensitizing chemical compounds and irradiation with, for example, UV radiation.Type: GrantFiled: April 16, 1991Date of Patent: August 30, 1994Assignee: Cryopharm CorporationInventors: Matthew S. Platz, Raymond P. Goodrich, Jr., Victoria A. Wong
-
Patent number: 5340819Abstract: Compounds of general formula I, ##STR1## and pharmaceutically acceptable salts thereof, in which R.sup.1 has any of the meanings given in the specification, pharmaceutical compositions comprising them and their use in the treatment of urinary incontinence.Type: GrantFiled: October 20, 1992Date of Patent: August 23, 1994Assignee: Imperial Chemical Industries plcInventors: Cyrus J. Ohnmacht, Robert J. Harris, Diane A. Trainor
-
Patent number: 5340818Abstract: The subject invention discloses methods of inhibiting growth of tumor cells which comprise contacting the cells with a growth inhibiting amount of a compound having one of following structures: ##STR1## wherein R.sup.1 is a hydroxyl or acetyl group; R.sup.2 is hydrogen, --CH.sub.2 --CH.dbd.C(CH.sub.3).sub.2 or a method group; R.sup.3 is a hydroxyl, methoxy or acetyl group; R.sup.4 is hydrogen, --CH.sub.2 --CH.dbd.C(CH.sub.3).sub.2 or a methoxy group; R.sup.5 is a hydroxyl, methoxy or acetyl group; is hydrogen or a hydroxyl, methoxy or acetyl group; and R.sup.10 is a methyl group, ##STR2## wherein R.sup.5 is hydrogen or --CH.sub.2 --CH.dbd.C(CH.sub.3).sub.2 ; R.sup.6 is a hydroxyl group; R.sup.10 is hydrogen or a hydroxyl group; R.sup.11 is a hydroxyl or methoxy group; and R.sup.12 is hydrogen or a methyl group.Type: GrantFiled: February 10, 1993Date of Patent: August 23, 1994Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Ting-Chao Chou, Tian-Shung Wu
-
Patent number: 5336485Abstract: Ionizable congeners of aromatic and aliphatic alcohols provide potent cytoprotective properties in vivo and in vitro. Alpha-tocopherol succinate, cholesteryl succinate, cholesteryl sulfate, dihydrocholesterol succinate, dihydrocholesterol sulfate, and ergosterol analogs are particularly good cytoprotective agents. In addition, the tris salts of these compounds have superior cytoprotective properties.Type: GrantFiled: March 10, 1993Date of Patent: August 9, 1994Assignees: Center for Innovative Technology, Virginia Commonwealth UniversityInventor: Marc W. Fariss
-
Patent number: 5312817Abstract: The use of a pharmaceutically acceptable cholinesterase inhibitor or a prodrug therefor for the treatment of fatigue syndromes, including chronic fatigue syndrome, post-infectious fatigue syndromes, fatigue syndromes associated with human immunodeficiency virus (HIV) infection or with preeclampsia. The acetyl cholinesterase is preferably one that acts substantially selectively at nicotinic receptor sites, and which has selectivity for acetyl cholinesterase as opposed to butyryl cholinesterase. Compounds of the invention include galanthamine and galanthamine derivatives.Type: GrantFiled: May 14, 1992Date of Patent: May 17, 1994Inventor: Ernir Snorrason
-
Patent number: 5312820Abstract: Carbamoyl and oxycarbonyl derivatives of biphenylmethylamines of structure I are angiotensin-II antagonists with balanced AT.sub.1 and AT.sub.2 activity useful in the treatment of hypertension and related disorders and ocular hypertension. ##STR1## where X is --O-- or --N(R.sup.7)--.Type: GrantFiled: July 17, 1992Date of Patent: May 17, 1994Assignee: Merck & Co., Inc.Inventors: Wallace T. Ashton, Linda L. Chang, William J. Greenlee, Steven M. Hutchins, Ralph A. Rivero
-
Patent number: 5294715Abstract: Hypoxia selective cytotoxins of the general formula ##STR1## wherein n is from 1 to 5, and NO.sub.2 is in at least one of the 2, 4 or 5-positions of the imidazole. Such compounds have utility as radiosensitizers and chemosensitizers.Type: GrantFiled: February 1, 1991Date of Patent: March 15, 1994Assignee: University of PittsburghInventors: Maria Papadopoulou-Rosenzweig, William D. Bloomer, William D. Bloomer
-
Patent number: 5284843Abstract: A method of inhibiting the abnormal postnatal axial growth of the eye of a maturing animal during conditions ordinarily leading to said abnormal growth, which comprises (1) determining the neurochemical present in the retina of said eye, eg., dopamine, the concentrations of which is reduced during said conditions, and (2) administering to said eye during post natal maturation effective amounts of said neurochemical, its agonist or its antagonist.Type: GrantFiled: April 10, 1991Date of Patent: February 8, 1994Assignees: Trustees of the University of Penna., Emory UniversityInventors: Richard A. Stone, Alan M. Laties, Paul M. Iuvone
-
Patent number: 5281611Abstract: An euthanasia solution based upon gamma-hydroxybutramide and a cardiotoxic amount of a compound selected from chloroquine and quinacrine is described. The composition provides effective euthanasia without unwanted side effects.Type: GrantFiled: December 19, 1990Date of Patent: January 25, 1994Assignee: Board of Trustees operating Michigan State UniversityInventors: Donald C. Sawyer, Theodore M. Brody, Marlee A. Langham
-
Patent number: 5258390Abstract: The invention provides the novel compound, 9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2H,5H)-acridinedione and pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions containing the compound, and the use of the compound in the treatment of urinary incontinence.Type: GrantFiled: October 20, 1992Date of Patent: November 2, 1993Assignee: Imperial Chemical Industries PLCInventor: Cyrus J. Ohnmacht
-
Patent number: 5240934Abstract: Quinoline derivatives of the formula, ##STR1## wherein >A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group, R.sup.2 is a hydrogen atom, a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, a phenyl group which may have a substituent, a phenoxy group, an alkanoyloxy group, or an amino group which may have a substituent, R.sup.3 is a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group, and m is an integer of 1-3. The compounds and their salts exhibit a superior anti-acetylcholinesterase activity with no side effects and are effective for the prevention or cure of senile dementia or memory disturbance.Type: GrantFiled: September 18, 1992Date of Patent: August 31, 1993Assignee: SS Pharmaceutical Co., Ltd.Inventors: Hiroshi Hasegawa, Kazuo Isomae, Takeshi Kotsugai, Noriaki Shioiri, Kumiko Sekine, Naokata Taido, Susumu Sato, Tadayuki Kuraishi
-
Patent number: 5240936Abstract: A novel compound for controlling (treatment and prevention) of ocular inflammation or systemic inflammatory disease is disclosed. The compound, OB-186, is effective at both the early and late phases of inflammation. The compound is useful for the treatment or prevention of inflammation in both the anterior and posterior portions of the eye and systemic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, glyomerulonephritis, allergic inflammation and allergic encephalomyelitis.Type: GrantFiled: May 14, 1992Date of Patent: August 31, 1993Assignee: Texas A&M University SystemInventor: George C. Y. Chiou